- Home
- BYSI vs HURA Comparison
BYSI vs HURA Comparison
Compare BYSI & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BYSI | HURA |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | United States |
| Employees | N/A | 19 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.9M | 79.6M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | BYSI | HURA |
|---|---|---|
| Price | $1.77 | $1.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 18.5K | ★ 789.9K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $0.41 |
| 52 Week High | $3.44 | $4.41 |
Technical Indicators
Market Signals| Indicator | BYSI | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 64.84 | 58.40 |
| Support Level | $1.68 | $1.66 |
| Resistance Level | $1.83 | $2.20 |
| Average True Range (ATR) | 0.13 | 0.21 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 90.62 | 74.86 |
Price Performance
Historical ComparisonAbout BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.